Therapeutic Options for Prostate Cancer: A Contemporary Update

2020 ◽  
pp. 234-263
Author(s):  
Sakthivel Muniyan ◽  
Jawed A. Siddiqui ◽  
Surinder K. Batra
Keyword(s):  
Prostate Cancer ◽  
Therapeutic Options

Current therapeutic options in metastatic castration-resistant prostate cancer

2018 ◽  
Vol 45 (5-6) ◽  
pp. 303-315 ◽  
Author(s):  
Gianluca Ingrosso ◽  
Beatrice Detti ◽  
Daniele Scartoni ◽  
Andrea Lancia ◽  
Irene Giacomelli ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Therapeutic Options ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

Abstract CC06-01: Identifying therapeutic options for patients with advanced prostate cancer through genes in liquid biopsies

2021 ◽  
Author(s):  
Seta Derderian ◽  
Edouard Jarry ◽  
Arynne Santos ◽  
Mohanachary Amaravadi ◽  
Quentin Vesval ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Advanced Prostate Cancer ◽  
Therapeutic Options ◽  
Liquid Biopsies

scholarly journals Prosztatarákban szenvedő betegek definitív ellátásának tanulságai és modern stratégiái

2018 ◽  
Vol 159 (32) ◽  
pp. 1317-1325
Author(s):  
Linda Varga ◽  
Zoltán Bajory ◽  
László Pajor ◽  
János Révész ◽  
Farkas Sükösd ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Carcinoma ◽  
Radical Surgery ◽  
Imaging Techniques ◽  
Late Complication ◽  
Three Dimensional ◽  
Therapeutic Options ◽  
Chronic Complications ◽  
Safety Margins ◽  
Prostate Carcinomas

Abstract: Introduction: Mortality of prostate carcinoma can be significantly decreased by the use of modern diagnostic and therapeutic options. Patients in early stages can be cured by radical surgery or radiotherapy. Aim: Overview and comparison of previous and present diagnostic and therapeutic methods regarding accuracy of diagnosis, improvement of efficiency and decrease of toxicities. We also aimed to explore general correlations in case of serious complications. Method: By the help of two prostate cancer patients we demonstrate the importance of accuracy and change of histological diagnosis, significance of proper imaging techniques, and also show parameters of conventional and modern radiotherapy and their acute and chronic complications. Differences of previous and present methods and their consequences were analyzed. Results: By now, histological findings in the patients’ diagnosis have changed. Both patients received conventional three-dimensional definitive radiotherapy in 2009–2011, and their prostate cancer was cured. In one case, urinary bladder also received radiotherapy because prostate carcinoma had infiltrated it. In the other case, the contemporary radiotherapy involved urinary bladder’s fundus due to safety margins. Although acute grade 2 cystitis developed in both cases and recovered in several weeks, as late complication bladder shrinkage developed, which after the ineffectiveness of conventional therapies had to be cured by radical cystoprostatectomy – in order to cease bleeding and to cure incontinence. Conclusions: In case of prostate carcinomas, serious complications can be avoided by the improvement of diagnostic and therapeutic options. Synthesis of data could be more successful if they were analyzed in the light of previous experiences. Orv Hetil. 2018; 159(32): 1317–1325.

Therapeutic options in advanced prostate cancer: Present and future

2007 ◽  
Vol 8 (1) ◽  
pp. 53-59 ◽  
Author(s):  
Richard D. Sowery ◽  
Alan I. So ◽  
Martin E. Gleave
Keyword(s):  
Prostate Cancer ◽  
Advanced Prostate Cancer ◽  
Therapeutic Options

scholarly journals Enhancing Prostate Cancer Care Through the Multidisciplinary Clinic Approach: A 15-Year Experience

2010 ◽  
Vol 6 (6) ◽  
pp. e5-e10 ◽  
Author(s):  
Leonard G. Gomella ◽  
Jianqing Lin ◽  
Jean Hoffman-Censits ◽  
Patricia Dugan ◽  
Fran Guiles ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Trial ◽  
Cancer Care ◽  
Therapeutic Options ◽  
Trial Participation ◽  
Educational Tool ◽  
Clinical Trial Participation ◽  
Multidisciplinary Clinic

The multidisciplinary clinic approach to prostate cancer may enhance outcomes and reduce “treatment regret” through a coordinated presentation of all therapeutic options. This model serves as an interdisciplinary educational tool for patients and their families, and supports clinical trial participation.

Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options

2015 ◽  
Vol 68 (5) ◽  
pp. 850-858 ◽  
Author(s):  
Benjamin A. Gartrell ◽  
Robert Coleman ◽  
Eleni Efstathiou ◽  
Karim Fizazi ◽  
Christopher J. Logothetis ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Therapeutic Options

Cost-effectiveness of upfront therapeutic options in low-volume de novo metastatic hormone-sensitive prostate cancer.

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 211-211
Author(s):  
Neil Rohit Parikh ◽  
Eric M. Chang ◽  
Nicholas George Nickols ◽  
Matthew Rettig ◽  
Ann C. Raldow ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Cost Effectiveness ◽  
Systemic Therapy ◽  
De Novo ◽  
Cost Effective ◽  
Therapeutic Options ◽  
Oral Drug ◽  
Hormone Sensitive ◽  
Low Volume

211 Background: Low-volume de novo metastatic hormone-sensitive prostate cancer (mHSPC) has historically been treated with lifelong androgen deprivation therapy (ADT). Recently, however, the addition of several advanced therapeutic options – radiation therapy (RT) to the primary, advanced hormonal therapy agents such as abiraterone acetate/prednisone (AAP), and chemotherapy – to ADT have been shown to improve survival in low-volume mHSPC. The objective of this study was to compare the cost-effectiveness of treating low-volume mHSPC patients upfront with RT+ADT, AAP+ADT, or docetaxel+ADT. Methods: A Markov-based cost-effectiveness analysis was constructed comparing three treatment strategies for low-volume mHSPC patients: (1) upfront RT+ADT --> salvage AAP+ADT --> salvage docetaxel+ADT; (2) upfront AAP+ADT --> salvage docetaxel+ADT, and (3) upfront docetaxel+ADT --> salvage AAP+ADT. Transition probabilities were calculated using data from STAMPEDE arms C/G/H, COU-AA-301, COU-AA-302, and TAX-327. RT was delivered via five-fraction stereotactic body radiation therapy. The analysis utilized a 10-year time horizon, and a $100,000/quality adjusted life year (QALY) willingness-to-pay threshold. Utilities were extracted from the literature; costs were taken from Medicare fee schedules and VA oral drug contracts. Results: At 10 years, total cost was $140K, $259K, and $189K, with total QALYs of 4.66, 5.03, and 3.72 for strategies (1) upfront RT+ADT, (2) upfront AAP+ADT, and (3) upfront docetaxel+ADT, respectively. Compared to upfront RT+ADT, upfront AAP+ADT was not cost-effective (ICER: $321K/QALY). This result remained unchanged even after modification of various model inputs in 1-way sensitivity analysis. Upfront docetaxel+ADT was both more costly and less effective than upfront RT+ADT (ICER: -$53K/QALY). Conclusions: At 10 years, RT+ADT is cost-effective compared to other advanced systemic therapy options alone, and should be considered as a viable treatment strategy in all patients with a low-burden of metastatic disease. Additional studies are needed to determine whether any benefit exists in combining RT to the primary with upfront advanced systemic therapy.

Sign in / Sign up

Export Citation Format

Share Document